Navigating Pregnancy with Diabetes: CGM Strategies for Success
March 20, 2024
Tune in to the latest episode of Real Time Real Talk with your host Cher Pastore, MS, RD, CDCES, BC-ADM. In this episode we take a deep and insightful look at the ever-evolving landscape of Continuous Glucose Monitoring (CGM) systems specifically within pregnancy with our guest, Dr Kristin Castorino. We explore in detail how this technology benefits pregnant patients with diabetes, focusing on the practicality of using devices like Dexcom G7 and how they aid both clinicians and patients in navigating this complex yet essential side of prenatal care.
Get a first-hand perspective on the benefits, challenges and the road ahead in diabetes care as Cher and Kristin delve into how CGM systems make data interpretation easier. They also discuss the data abundance and the changes needed to mitigate the information overload it can often cause. Finally, Kristin discusses common misconceptions about CGM, the key role played by insurance coverage in the adoption of CGMs, and takes a look into the promising developments in the near future.
From debunking myths and clarifying concerns about CGM to emphasizing how this technology feeds into a more integrated care environment, this is an episode you won't want to miss.
Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes paper: https://pubmed.ncbi.nlm.nih.gov/38315503/
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Kristin Castorino, MD is a paid spokesperson for Dexcom.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom Clarity Clinic Login: https://clarity.dexcom.com/professional/
Dexcom Provider website: https://provider.dexcom.com
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
References:
1. Polsky S, Valent A, Isganaitis E, Castorino K, O'Malley G, Beck S, Gao P, Laffel LM, Brown FM, Levy C. Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2024 Feb 5. doi: 10.1089/dia.2023.0516. Epub ahead of print. PMID: 38315503.
2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110. doi: 10.2337/dc23-S006. PMID: 36507646; PMCID: PMC9810469.
Tune in to the latest episode of Real Time Real Talk with your host Cher Pastore, MS, RD, CDCES, BC-ADM. In this episode we take a deep and insightful look at the ever-evolving landscape of Continuous Glucose Monitoring (CGM) systems specifically within pregnancy with our guest, Dr Kristin Castorino. We explore in detail how this technology benefits pregnant patients with diabetes, focusing on the practicality of using devices like Dexcom G7 and how they aid both clinicians and patients in navigating this complex yet essential side of prenatal care.
Get a first-hand perspective on the benefits, challenges and the road ahead in diabetes care as Cher and Kristin delve into how CGM systems make data interpretation easier. They also discuss the data abundance and the changes needed to mitigate the information overload it can often cause. Finally, Kristin discusses common misconceptions about CGM, the key role played by insurance coverage in the adoption of CGMs, and a look into the promising developments in the near future.
From debunking myths and clarifying concerns about CGM to emphasizing how this technology feeds into a more integrated care environment, this is an episode you won't want to miss.
Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes paper: https://pubmed.ncbi.nlm.nih.gov/38315503/
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Kristin Castorino, MD is a paid spokesperson for Dexcom.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom Clarity Clinic Login: https://clarity.dexcom.com/professional/
Dexcom Provider website: https://provider.dexcom.com
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
References:
1. Polsky S, Valent A, Isganaitis E, Castorino K, O'Malley G, Beck S, Gao P, Laffel LM, Brown FM, Levy C. Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2024 Feb 5. doi: 10.1089/dia.2023.0516. Epub ahead of print. PMID: 38315503.
2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110. doi: 10.2337/dc23-S006. PMID: 36507646; PMCID: PMC9810469.
Get a first-hand perspective on the benefits, challenges and the road ahead in diabetes care as Cher and Kristin delve into how CGM systems make data interpretation easier. They also discuss the data abundance and the changes needed to mitigate the information overload it can often cause. Finally, Kristin discusses common misconceptions about CGM, the key role played by insurance coverage in the adoption of CGMs, and a look into the promising developments in the near future.
From debunking myths and clarifying concerns about CGM to emphasizing how this technology feeds into a more integrated care environment, this is an episode you won't want to miss.
Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes paper: https://pubmed.ncbi.nlm.nih.gov/38315503/
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Kristin Castorino, MD is a paid spokesperson for Dexcom.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom Clarity Clinic Login: https://clarity.dexcom.com/professional/
Dexcom Provider website: https://provider.dexcom.com
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
References:
1. Polsky S, Valent A, Isganaitis E, Castorino K, O'Malley G, Beck S, Gao P, Laffel LM, Brown FM, Levy C. Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2024 Feb 5. doi: 10.1089/dia.2023.0516. Epub ahead of print. PMID: 38315503.
2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110. doi: 10.2337/dc23-S006. PMID: 36507646; PMCID: PMC9810469.